Posted on August 27 at 6:29 p.m.

GenoMed, a genomics-based Disease Management company in St. Louis, has had encouraging results treating West Nile virus encephalitis since 2003.

We’ve had about 80% treatment success rate in people (23 of 29 improved) and horses (8 of 10 survived), and 50% in birds (6 of 12 survived). Our first 8 human WNV patients were published in a peer-reviewed medical journal in 2004 (1). This is sufficient for our treatment to officially exist in both the medical and legal senses.

The earlier our treatment is begun, the better the outcome.

Anybody who wants to download our WNV trial protocol can do so for free at any time by clicking on the "West Nile trial" link on our company’s homepage at www.genomed.com.

Dave Moskowitz MD
CEO & Chief Medical Officer
GenoMed, Inc. (Ticker symbol GMED on OTC Pink Sheets)
“The public health company™”

1. Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 (For PDF file, click on paper #6 at: http://www.genomed.com/index.cfm?action=...)

On Crow Tests Positive for West Nile Virus

Posted on May 3 at 8:19 a.m.

My biotech company has had encouraging results treating West Nile virus encephalitis since 2003: 81% treatment success rate in people (22 of 27), 75% in horses (6 of 8), and 50% in birds (6 of 12).

Our approach works best when people first have symptoms of a fever and headache. But we’ve been able to help people even a few years after the initial episode of WNV encephalitis.

Our first 8 WNV patients were published in a peer-reviewed medical journal in 2004 (1). We’re eager to see if our approach works again this year.

The drugs we use are already approved by the FDA for blood pressure. They seem to be anti-inflammatory, too. People with a normal immune system who get sick from the West Nile virus appear to overdo their immune response to the virus. Our approach is meant to gently calm down their exaggerated immune response, the so-called “cytokine storm.” It can be used in the very old, the very young, and everybody in between.

It can also be used for almost any virus except the herpes viruses, which is why our approach was included in the BioShield II Act of April 28, 2005, co-sponsored by Senators Lieberman, Hatch, and Brownback. The bill was never debated, but our approach was mentioned in Section 2151 (http://www.govtrack.us/congress/billtext...). In 2004, I briefed the White House and the Dept of Homeland Security about it. The UN is aware of our approach in the context of bird flu, although they haven’t tested it, preferring to push Roche’s drug Tamiflu instead.

The drugs we use cost about $1 a tablet. We use one or two pills a day. They’re carried in every drugstore on earth. You have to admit, if it works, that this would be a pretty sweet deal for public health!

Anybody who wants to download our WNV trial protocol can do so for free at any time by clicking on the "West Nile trial" link on our company’s homepage at www.genomed.com.

Reference

1: Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 (For PDF file, click on paper #6 at: http://www.genomed.com/index.cfm?action=...) -- see Table 2 for WNV patients

Sincerely,
Dave Moskowitz MD FACP
CEO, GenoMed, Inc.
www.genomed.com
“The public health company™”
Ticker symbol: GMED (on the Pink Sheets)

On UCSB Researchers Focus on Animal-to-Human Disease Shifts